Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Author: kodiac

BPC-157

Plain-language summaryIntrigue 78 / 100

BPC-157 is a small protein fragment originally isolated from human stomach acid. Researchers found that it speeds up healing of injured tendons, ligaments, muscles, and gut tissue in animal studies. It is one of the most popular peptides in injury recovery research, though human clinical trials are limited. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundSingle-lab provenance

44/100

Multi-system repair peptide with real biological interest but single-lab evidence base limits confidence

Look, BPC-157 is one of those compounds where the interesting science and the evidence quality live in completely different zip codes. The 15-residue sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) was pulled from a larger gastric protective protein in human gastric juice, and the Sikiric group at the University of Zagreb spent the better part of three decades building a preclinical record across tendon transection models, gut mucosal protection, vascular reorganization, and dopaminergic modulation. That’s a wide net. Maybe too wide.

What we actually like about the chemistry here is the multi-system profile. VEGF-R2 engagement for angiogenesis, nitric oxide synthase modulation, GH receptor crosstalk, dopaminergic system effects: these aren’t trivial mechanisms to pin on one compound. The oral bioavailability story is genuinely surprising for a 15-amino acid peptide; most sequences this length get destroyed in the gut, and the hypothesis that BPC-157 survives because it evolved as a gut-protective compound is at least coherent. If that holds reliably, it makes BPC-157 unusually interesting as an orally-active probe for tissue repair models, and thats not a small advantage in practice.

The problem is literature provenance. The Sikiric group isn’t just the dominant contributor to BPC-157 research, they’re essentially the entire enterprise. Independent multi-lab replication of the core findings is limited, and when a single research consortium has authored the bulk of the positive preclinical record, you cannot confidently read through the effect sizes and know what’s real versus what’s a lab-specific artifact. We’ve seen this pattern elsewhere: Cerebrolysin has an analogous Eastern European single-consortium problem, and it makes mechanism claims, dose-response estimates, and cross-species generalizations all suspect. Growing replication exists, but we’re not there yet.

Human data is nearly absent. One published Phase 1 single-ascending-dose study is the entire clinical record. No Phase 2 efficacy data, no multi-site trials. The translational arrow points somewhere interesting, but you can’t see how far it reaches from here.

For bench investigators, BPC-157 still has real utility as a probe in tissue repair and gastrointestinal mucosal models. The rodent protocols are well-documented, the peptide synthesizes to high purity, and the multi-system effects give you genuine research surface area. But you’re buying into a single-lab evidence base, and any conclusions you draw need to be treated as hypothesis-generating rather than hypothesis-confirming. Independent replication is what this compound needs more than anything right now, and investigators willing to run that work cleanly would be doing something actually useful for the field. Honest position: compelling enough to study, constrained enough to score modestly.

Novelty

44

Mechanism promise

55

In-category differentiation

50

Evidence quality

28

Translational signal

30

Research bench value

52

Rationale BPC-157 scores modestly on evidence quality (28) and translational signal (30) because the Sikiric group at Zagreb has authored the overwhelming majority of the positive preclinical record, with independent multi-lab replication remaining limited; mechanism and differentiation pull the overall up because the multi-target profile and unexpected oral bioavailability story are genuinely interesting, but the single-consortium provenance prevents the compound from scoring in the established-active range.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Pentadecapeptide (gastric BPC fragment)

A 15-amino-acid sequence derived from a gastric protective protein, broadly studied in tendon, ligament, vascular, and gut repair models.

Abstract

BPC-157, formally pentadecapeptide BPC 157 (Body Protection Compound 157), is a 15-residue partial sequence isolated from a larger gastric protective protein found in human gastric juice. The sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (CAS 137525-51-0; molecular formula C62H98N16O22; molecular weight 1419.55) was originally characterized in the 1990s by the Sikiric group at the University of Zagreb, who have authored the majority of the published preclinical record. Reported activities span tendon and ligament healing in transection models, vascular reorganization through nitric oxide synthase modulation and VEGF receptor 2 engagement, gastrointestinal mucosal protection, dopaminergic system modulation, and GH receptor crosstalk. Routes studied include intraperitoneal, intramuscular, subcutaneous, oral, and topical administration in rodent models; oral bioavailability is unusual for a peptide of this length and is attributed to the parent compound’s evolutionary role in the gut. Human pharmacokinetic data are sparse; one published Phase 1 single-ascending-dose study has been reported. BPC-157 is not approved by any regulatory authority for human or veterinary use. The literature base is dominated by a single research group, which is the principal limitation on the strength of the evidence; independent replications of the most-cited findings are limited but growing. This monograph reviews the chemistry, mechanism, pharmacokinetics, dosing literature, sourcing risks, and reconstitution practice for in vitro and in vivo investigative work.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-002Open in new tab →

Download PDF →

Acquire BPC-157 from the catalog

View BPC-157 →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 8, 2026
9-Me-BC

Plain-language summaryIntrigue 64 / 100

9-Me-BC (9-methyl-beta-carboline) is a small molecule based on the beta-carboline scaffold. Research suggests it has dopaminergic neuroprotective effects, with potential implications in Parkinson disease research. Capsule format here. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundSingle-lab provenance

44/100

Genuine dopaminergic neuroprotective signal, but single-consortium evidence and zero human data cap the research priority

Look, the mechanism story here is genuinely worth reading. 9-Me-BC sits inside the beta-carboline family but the 9-position methylation does something important: it substantially reduces MAO-A affinity relative to harmine or harmaline and strips away most of the psychoactive profile those relatives carry. What you get instead is a compound characterized for dopaminergic neuroprotective effects, increased dopamine neuron differentiation in cell culture, and elevated BDNF expression in rodent brain tissue. For anyone running experiments on dopaminergic system maintenance or neurotrophic factor dynamics, that combination is a real signal worth paying attention to.

The differentiation angle matters for experimental design. If youre trying to probe dopaminergic neuroprotection without MAO-A pharmacology confounding your readout, 9-Me-BC carves out a reasonably clean space. The 182 Da molecular weight and reported oral bioavailability make it easier to work with than peptide-based approaches to adjacent questions. The BDNF connection adds a second axis that could be useful for designs crossing dopaminergic and neurotrophic factor biology.

Here’s the thing though: when you actually audit where the evidence comes from, the limitations are serious. The research record dates to the 2010s and is dominated by a small cluster of German neuroscience labs. Thats not a fatal problem on its own, but there is no independent multi-lab replication that would let you trust the effect sizes, and there is no human clinical data at all. Not preliminary phase 1 work, not small-N observational, nothing. So you have an interesting mechanism and rodent plus cell culture data from a single research community, and the translational arrow is pointing at a question mark.

We’ve seen this pattern before. The BPC-157 literature has the same structural problem, and the credibility of that body of work has aged in ways that should make any serious investigator cautious about single-consortium signals. 9-Me-BC isn’t in worse shape than BPC-157, but it isn’t clearly in better shape either, and the research record is shorter.

Honestly, this is a compound worth monitoring. If independent labs begin replicating the dopaminergic differentiation findings, the score changes. Right now, the mechanism promise earned it a real look; the evidence base hasn’t earned priority placement in an active research program. Worth knowing about. Not worth leading with.

Novelty

62

Mechanism promise

57

In-category differentiation

44

Evidence quality

22

Translational signal

18

Research bench value

50

Rationale The 9-position methylation creates a meaningfully distinct pharmacological profile from classic psychoactive beta-carbolines, with real dopaminergic neuroprotection and BDNF signal in rodent work. However, the published record is dominated by a tight cluster of German labs with no independent multi-lab replication and no human clinical data of any kind, pulling evidence and translational scores to the floor.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Beta-carboline alkaloid, dopaminergic neuroprotective small molecule (capsule format)

A 182 Da methylated beta-carboline alkaloid characterized for dopaminergic neuroprotective effects, increased dopamine neuron differentiation, and BDNF expression in animal models. Supplied as 30 capsules x 20 mg.

Abstract

9-Methyl-beta-carboline (9-Me-BC; CAS 2521-07-5; molecular formula C12H10N2; molecular weight 182.22) is a small-molecule beta-carboline alkaloid bearing a methyl substituent on the 9-position indole nitrogen. The compound is a member of the broader beta-carboline family, naturally occurring alkaloids found in trace concentrations in many plants (notably the harmal family of psychoactive plants used in traditional preparations) and present at low concentrations in mammalian tissues including human plasma. The synthetic 9-methylated variant has attracted research interest beginning in the 2010s for a distinctive pharmacological profile that combines dopaminergic neuroprotective effects, increased dopamine neuron differentiation in cell culture, and elevated BDNF expression in rodent brain. Unlike many psychoactive beta-carbolines (harmaline, harmine, others), 9-Me-BC has substantially reduced affinity for the monoamine oxidase A enzyme and substantially reduced psychoactive effects at the doses used in published preclinical work. The compound is supplied at Kodiac biolabs as a 30-capsule oral preparation, 20 milligrams per capsule, reflecting the small molecule’s stability and good oral bioavailability. There is no FDA-approved IND for 9-Me-BC in any indication. The principal limitations on the strength of the evidence are the relatively short duration of the published research record, dominance of a small number of laboratories (primarily in the German neuroscience research community), and the absence of human clinical data.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-015Open in new tab →

Download PDF →

Acquire 9-Me-BC from the catalog

View 9-Me-BC →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 8, 2026

←Previous Page

1 … 67 68 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.